<DOC>
	<DOCNO>NCT00053508</DOCNO>
	<brief_summary>The purpose study examine safety effectiveness new vaccine prevention disease , smallpox .</brief_summary>
	<brief_title>Dose Safety , Tolerability , Immunogenicity New Smallpox Vaccine Adults Without Previous Smallpox Vaccination</brief_title>
	<detailed_description>In addition assessment safety parameter , objective study determine minimum dose ACAM1000 calculate produce major cutaneous reaction least 90 % population healthy adult 18-29 year age naïve smallpox vaccine . Specifically , objective study : 1 . Compare safety tolerability three dose level ACAM1000 standard dose Dryvax® healthy adult 18-29 year age naïve smallpox vaccine . Safety tolerability determine examination local cutaneous reaction , adverse event , physical examination , vital sign , structure interview , laboratory analysis . 2 . Determine immunogenicity three dose level ACAM1000 standard dose Dryvax® healthy adult 18-29 year age comparing : ( ) proportion subject dose level develop major cutaneous reaction ; ( b ) proportion subject treatment group develop neutralizing antibody , include fold-increase antibody titer Baseline Day 30 serum ; geometric mean vaccinia neutralize antibody titer Day 30 . 3 . Determine minimum dose ACAM1000 calculate produce major cutaneous reaction least 90 % population healthy adult 18-29 year age naïve smallpox vaccine .</detailed_description>
	<mesh_term>Smallpox</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Inclusion criterion : good general health . pregnant use effective birth control agree participate entire study comply protocol requirement . Exclusion criterion : military service prior 1989. previous smallpox vaccination . contact child 1 year age young immunodeficiency individual close contact immunodeficient past history current renal disease diagnosis past history eczema know allergy past allergic reaction latex glove antibiotic ( neomycin , streptomycin , chlortetracycline , polymyxin B ) . know allergy past allergic blood product . know allergy past allergic reaction cidofovir sulfacontaining drug . transfusion blood treatment blood product , include intramuscular intravenous serum globulin within six month Screening Visit . serology positive HIV , hepatitis B hepatitis C. current diagnosis history within six month drug alcohol abuse disorder , psychiatric illness . inoculation live vaccine within 30 day Day 0 participation another drug vaccine trial within 30 day Day 0 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>29 Years</maximum_age>
	<verification_date>January 2014</verification_date>
</DOC>